Pol F. Boudes - 24 Jan 2022 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Role
Chief Medical Officer
Signature
Jack W. Callicutt, by power of attorney
Issuer symbol
GALT
Transactions as of
24 Jan 2022
Net transactions value
$0
Form type
4
Filing time
25 Jan 2022, 15:17:48 UTC
Next filing
09 Sep 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GALT Stock Option (right to buy) Award $0 +50,000 $0.000000 50,000 24 Jan 2022 Common Stock 50,000 $1.98 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.
F2 The options vest as follows: 25% on each of June 30, 2022; December 31, 2022; June 30, 2023; and December 31, 2023.